BioSpace News Archive

Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive innovation, today announced expansion of the company’s existing strategic collaboration in fibrosis with Bayer AG.

IO Biotech announced today that it has entered into a third clinical trial collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada), through a subsidiary.

BioPlus Acquisition Corp. (the “Company”) announced today that it priced its upsized initial public offering of 20,000,000 units at $10.00 per unit.

Remix Therapeutics today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix Therapeutics, will deliver a presentation highlighting the Company’s approaches to modulating RNA processing with small molecules at the 4th Annual RNA-Targeted Drug Discovery Summit.

Vincerx Pharma, Inc. (Nasdaq: VINC), today announced that it will host a key opinion leader (KOL) webinar to discuss the data presented on the Company’s lead asset, VIP152, in chronic lymphocytic leukemia (CLL) and diffuse large B-Cell lymphoma (DLBCL) at the 63rd American Society of Hematology (ASH) Annual Meeting.

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart defect in infants.

H-CYTE, Inc., a medical biosciences company focused on the field of regenerative medicine, announced that it has named Michael Yurkowsky as its Chief Executive Officer effective immediately.

NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), today announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada) to evaluate NGM707, NGM’s wholly-owned novel ILT2/ILT4 dual antagonist antibody, in combination with Merck’s anti-PD-1 therapy,

The new omicron variant is a game changer as current vaccine producers have recognized that new SARS-CoV-2 vaccines will be necessary to combat this new threat.

Acurx Pharmaceuticals, Inc. announced today that the first patient has been enrolled in its Phase 2b clinical trial of ibezapolstat, its lead antibiotic candidate, against the standard of care to treat CDI, vancomycin, in a 64 patient double-blind randomized trial expected to be completed mid-2022.